Search for content, post, videos

AroCell has submitted a new patent application

Michael Brobjer

A patent application has been submitted regarding the use of an immunoassay of Thymidine Kinase 1 (TK1) to enable more accurate prognoses in prostate cancer patients.

In the study, on which this patent application is based, TK1 protein levels were assayed with AroCell TK 210 ELISA in serum samples collected from subjects with newly diagnosed prostate cancer and compared with the extent and speed of disease progression over a period of 10 years. The study was executed in collaboration with the Prostate Research Center at Tampere University Hospital and coordinated by Professor Teemu Murtola of the Pharmacoepidemiology and Chemoprevention of Urological Cancer Research Group.

“Thymidine kinase 1 in serum predicted survival after prostate cancer diagnosis, demonstrating independent predictive value over established clinical risk factors. If confirmed in further and larger studies, this biomarker could be incorporated in prostate cancer risk stratification when selecting optimal treatment and surveillance schedule,” says Professor Teemu Murtola.

Strengthens AroCell’s position as a developer and promoter of novel biomarkers for monitoring cancer

“Prostate cancer is one of the most common cancers in men and this patent strengthens AroCell’s position as a developer and promoter of novel biomarkers for monitoring cancer. The patent will reinforce our position and increases AroCell’s attractiveness as a business partner. We will continue to develop our proprietary portfolio to further expand our business opportunities,” says Michael Brobjer, CEO AroCell.

Photo of Michael Brobjer: AroCell